Cargando…

Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review

The eyebrows frame the upper margin of the orbit and are an essential feature of the facial landscape. Eyebrow hypotrichosis, also known as madarosis, is characterized by a lack of growth or loss of eyebrow hair. Eyebrow loss can have cosmetic, functional, and social consequences. Eyebrow hypotricho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riahi, Ryan R, Cohen, Philip R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2018
Materias:	Dermatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054329/ https://www.ncbi.nlm.nih.gov/pubmed/30042917 http://dx.doi.org/10.7759/cureus.2666

Ejemplares similares

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis
por: Carruthers, Jean, et al.
Publicado: (2016)

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
por: Zaky, Mohamed S., et al.
Publicado: (2023)

Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis
por: Chanasumon, Nongsak, et al.
Publicado: (2018)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Bimatoprost in the treatment of eyelash hypotrichosis
por: Law, Simon K
Publicado: (2010)

Floppy eyelid syndrome and ectropion improvement after 1 month of 0.03% Bimatoprost topical therapy
por: De Gregorio, Alessandra, et al.
Publicado: (2020)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Management of hypotrichosis of the eyelashes: Focus on bimatoprost
por: Fagien, Steven
Publicado: (2010)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study
por: Deshpande, Sarita S, et al.
Publicado: (2017)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial
por: Glaser, D.A., et al.
Publicado: (2015)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat, Lutz E, et al.
Publicado: (2016)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Sister Mary Joseph Nodule as a Cutaneous Manifestation of Metastatic Appendiceal Adenocarcinoma: Case Report and Literature Review
por: Girijala, Raghavendra L, et al.
Publicado: (2018)

Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: A preliminary study
por: Vyas, Prateep, et al.
Publicado: (2011)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
por: Wirta, David, et al.
Publicado: (2011)

Chronic Granulomatous Reaction to Semi-permanent Eyebrow Tint
por: Suleman, Saba, et al.
Publicado: (2023)

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
por: Wang, Kaidi, et al.
Publicado: (2014)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

Heater-Associated Erythema Ab Igne: Case Report and Review of Thermal-Related Skin Conditions
por: Forouzan, Parnia, et al.
Publicado: (2020)

Atorvastatin-induced Lichenoid Drug Eruption: A Case Report and Review of Statin-associated Cutaneous Adverse Events
por: Forouzan, Parnia, et al.
Publicado: (2020)

Hypertrophic Lichen Planus Mimicking Verrucous Lupus Erythematosus
por: Riahi, Ryan R, et al.
Publicado: (2018)

Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis
por: Hazarika, Ajit Kumar, et al.
Publicado: (2015)

Successful Treatment of Recalcitrant Granuloma Gluteale Infantum with Topical Tacrolimus 0.03% Ointment
por: Leung, Alexander K. C., et al.
Publicado: (2021)

Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%
por: Georgakopoulou, Eleni, et al.
Publicado: (2021)

Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study
por: Petricca, Sabrina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ug1c1hnef50sh5p0v9erlfjfka